

Haematologica
HAEMATOL/2014/115691
Version 3
c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine
kinase activity in chronic myeloid leukemia

Disclosures: REC has received research funding from Novartis, Bristol Myers Squibb, Pfizer and (not related to this publication) Sanofi, and is a member of the speakers bureau for Novartis and (not related to this publication) Sanofi.

Contributions: CML performed experiments, designed the study and wrote the manuscript. AG performed experiments. RJH and REC designed the study and wrote the manuscript. We would like to thank Elizabeth McDonald and Natasha Carmell for their technical help.